Proof-of-Concept Double-Blind Placebo-Controlled Trial Measuring Cartilage Composition in Early Rheumatoid Arthritis...

Area of Science:

• Rheumatology
• Radiology
• Biochemistry

Background:

• Low delayed gadolinium-enhanced magnetic resonance imaging of cartilage (dGEMRIC) values indicate cartilage degeneration.
• Early rheumatoid arthritis (RA) patients exhibit low dGEMRIC values due to inflammation.
• The impact of biological disease-modifying antirheumatic drugs (bDMARDs) and conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) on cartilage in early RA is not fully understood.

Purpose of the Study:

• To investigate the effect of methotrexate plus adalimumab versus methotrexate alone on cartilage integrity in early RA patients.
• To assess changes in dGEMRIC values as a measure of cartilage composition over 24 weeks.

Main Methods:

• Prospective, double-blinded, randomized proof-of-concept clinical trial.
• Early RA patients (disease duration < 12 months) received methotrexate + adalimumab (n=10) or methotrexate alone (n=4).
• Cartilage integrity in metacarpophalangeal joints was evaluated using dGEMRIC at baseline, 12, and 24 weeks.

Main Results:

• The adalimumab group demonstrated a statistically significant increase in dGEMRIC levels at 12 and 24 weeks (p < 0.05).
• The methotrexate-alone group showed no significant change in dGEMRIC levels.
• A trend towards improved cartilage composition was observed with combination therapy after 24 weeks, while methotrexate alone showed a slight decrease.

Conclusions:

• Combination therapy with methotrexate and adalimumab shows a trend towards improving cartilage composition in early RA patients.
• Methotrexate monotherapy did not demonstrate significant changes in cartilage composition over 24 weeks.
• These findings suggest potential benefits of bDMARDs in preserving cartilage integrity in early RA.